Outcome-Based Pricing for New Pharmaceuticals via Rebates

References

• AAM (2018) 2018 Generic drug access & savings in the U.S.: Access in jeopardy. Technical report, Association for Accessible Medicines, Washington, DC. Accessed February 13, 2019, https://accessiblemeds.org/sites/default/files/2018_aam_generic_drug_access_and_savings_report.pdf.Google Scholar
• Adida E, Bravo F (2019) Contracts for healthcare referral services: Coordination via outcome-based penalty contracts. Management Sci. 65(3):1322–1341.Google Scholar
• Adida E, Mamani H, Nassiri S (2017) Bundled payment vs. fee-for-service: Impact of payment scheme on performance. Management Sci. 63(5):1606–1624.Link, Google Scholar
• AHA (2017) Cardiovascular disease: A costly burden for America—Projections through 2035. American Heart Association CVD Burden Report, American Heart Association, Washington, DC. Accessed February 14, 2019, http://www.heart.org/idc/groups/heart-public/@wcm/@adv/documents/downloadable/ucm_491543.pdf.Google Scholar
• Amgen (2017) Amgen and Harvard Pilgrim agree to first cardiovascular outcomes-based refund contract for Repatha® (evolocumab). Accessed February 15, 2019, https://www.amgen.com/media/news-releases/2017/05/amgen-and-harvard-pilgrim-agree-to-first-cardiovascular-outcomesbased-refund-contract-for-repatha-evolocumab/.Google Scholar
• Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, Halperin JL, et al.. (2014) ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: A report of the American College of Cardiology/American Heart Association task force on performance measures and task force on practice guidelines. J. Amer. College Cardiology 63(21):2304–2322.Crossref, Google Scholar
• Andritsos DA, Tang CS (2018) Incentive programs for reducing readmissions when patient care is co-produced. Production Oper. Management 27(6):999–1020.Crossref, Google Scholar
• Antonanzas F, Juarez-Castello C, Rodriguez-Ibeas R (2011) Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Econom. Policy Law 6(3):391–403.Crossref, Google Scholar
• Barros PP (2011) The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry. Health Econom. 20(4):461–470.Crossref, Google Scholar
• Brody JE (2017) The cost of not taking your medicine. New York Times (April 17), https://www.nytimes.com/2017/04/17/well/the-cost-of-not-taking-your-medicine.html.Google Scholar
• Cachon GP, Lariviere MA (2005) Supply chain coordination with revenue-sharing contracts: Strengths and limitations. Management Sci. 51(1):30–44.Link, Google Scholar
• Cancer Treatment Centers of America (2018) What’s the difference? Biosimilar and generic drugs. Accessed February 13, 2019, https://www.cancercenter.com/community/blog/2018/12/whats-the-difference-biosimilar-and-generic-drugs.Google Scholar
• Carlson JJ, Garrison LP Jr, Sullivan SD (2009) Paying for outcomes: Innovative coverage and reimbursement schemes for pharmaceuticals. J. Managed Care Pharmacy 15(8):683–687.Crossref, Google Scholar
• Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL (2010) Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 96(3):179–190.Crossref, Google Scholar
• CMS (2017) CMS: Innovative treatments call for innovative payment models and arrangements. Press release, Centers for Medicare & Medicaid Services, Baltimore. Accessed February 15, 2019, https://www.cms.gov/Newsroom/MediaReleaseDatabase/Press-releases/2017-Press-releases-items/2017-08-30-2.html.Google Scholar
• CMS (2018) CMS national health expenditure data. Accessed February 15, 2019, https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical.html.Google Scholar
• Davis S, Gerstner E, Hagerty M (1995) Money back guarantees in retailing: Matching products to consumer tastes. J. Retailing 71(1):7–22.Crossref, Google Scholar
• Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, et al. (2017) Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiology 2(10):1069–1078.Crossref, Google Scholar
• Fox E (2017) How pharma companies game the system to keep drugs expensive. Harvard Bus. Rev. (April 6), https://hbr.org/2017/04/how-pharma-companies-game-the-system-to-keep-drugs-expensive.Google Scholar
• Garber AM, McClellan MB (2007) Satisfaction guaranteed—“payment by results” for biologic agents. New England J. Medicine 357(16):1575–1577.Crossref, Google Scholar
• Garrison LP Jr, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, Severens JL, Silviero P, Sleeper M (2013) Performance-based risk-sharing arrangements—Good practices for design, implementation, and evaluation: Report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health 16(5):703–719.Crossref, Google Scholar
• Gatlin A (2018) Regeneron is undercutting Amgen in cholesterol drugs—Will it help share? Investor’s Bus. Daily (May 1), https://www.investors.com/news/technology/regeneron-praluent-price-cut/.Google Scholar
• Gellad WF, Kesselheim AS (2017) Accelerated approval and expensive drugs—A challenging combination. New England J. Medicine 376(21):2001–2004.Crossref, Google Scholar
• GoodRx (2019) Repatha Medicare formulary information & restrictions. Accessed February 15, 2019, https://www.goodrx.com/repatha/medicare-coverage.Google Scholar
• Guo P, Tang CS, Wang Y, Zhao M (2019) The impact of reimbursement policy on social welfare, revisit rate, and waiting time in a public healthcare system: Fee-for-service vs. bundled payment. Manufacturing Service Oper. Management 21(1):154–170.Link, Google Scholar
• Hardie BGS, Johnson EJ, Fader PS (1993) Modeling loss aversion and reference dependence effects on brand choice. Marketing Sci. 12(4):378–394.Link, Google Scholar
• HHS (2018) American patients first: The Trump administration blueprint to lower drug prices and reduce out-of-pocket costs. Department of Health and Human Services, Washington, DC. Accessed February 15, 2019, https://www.hhs.gov/sites/default/files/AmericanPatientsFirst.pdf.Google Scholar
• HRI (2018) Health Research Institute regulatory insight. Accessed February 13, 2019, https://www.pwc.com/us/en/health-industries/health-research-institute/pdf/pwc-health-research-institute-generic-drug-pricing-june-2018.pdf.Google Scholar
• Husten L (2018) The ODYSSEY trial ends well—but will it be enough? CardioBrief (March 10), http://www.cardiobrief.org/2018/03/10/the-odyssey-trial-ends-well-but-is-it-enough/.Google Scholar
• IQVIA (2018) Medicine use and spending in the U.S.: A review of 2017 and outlook to 2022. Institute report, IQVIA Institute for Human Data Science, Danbury, CT.Google Scholar
• Jiang H, Pang Z, Savin S (2012) Performance-based contracts for outpatient medical services. Manufacturing Service Oper. Management 14(4):654–669.Link, Google Scholar
• Kahneman D, Tversky A (1979) Prospect theory: An analysis of decision under risk. Econometrica 47(2):263–291.Crossref, Google Scholar
• Kaplan S, Thomas K (2017) Draft order on drug prices proposes easing regulations. New York Times (June 20), https://www.nytimes.com/2017/06/20/health/draft-order-on-drug-prices-proposes-easing-regulations.html.Google Scholar
• KFF (2015) Kaiser health tracking poll: August 2015. Henry J. Kaiser Family Foundation, Washington, DC. Accessed February 15, 2019, https://www.kff.org/health-costs/poll-finding/kaiser-health-tracking-poll-august-2015/.Google Scholar
• KFF (2016) 2016 Employer health benefits survey. Henry J. Kaiser Family Foundation, Washington, DC. Accessed February 15, 2019, https://www.kff.org/report-section/ehbs-2016-section-nine-prescription-drug-benefits/.Google Scholar
• Lee DKK, Zenios SA (2012) An evidence-based incentive system for Medicare’s end-stage renal disease program. Management Sci. 58(6):1092–1105.Link, Google Scholar
• Lenert LA, Treadwell JR, Schwartz CE (1999) Associations between health status and utilities implications for policy. Medical Care 37(5):479–489.Crossref, Google Scholar
• Lilico A (2003) Risk sharing pricing models in the distribution of pharmaceuticals. Working paper, Europe Economics, London.Google Scholar
• Loftus P (2017) Drug companies tie costs to outcomes. Wall Street Journal (September 12), https://www.wsj.com/articles/drug-companies-tie-costs-to-outcomes-1505268421.Google Scholar
• Mahjoub R, Ødegaard F, Zaric GS (2018) Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success. Health Econom. 27(1):e15–e25.Crossref, Google Scholar
• Møldrup C (2005) No cure, no pay. BMJ 330:1262–1264.Crossref, Google Scholar
• Moorthy S, Srinivasan K (1995) Signaling quality with a money-back guarantee: The role of transaction costs. Marketing Sci. 14(4):442–466.Link, Google Scholar
• Navar AM, Taylor B, Mulder H, Fievitz E, Monda KL, Fievitz A, Maya JF, López JAG, Peterson ED (2017) Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy. JAMA Cardiology 2(11):1217–1225.Crossref, Google Scholar
• Navarria A, Drago V, Gozzo L, Longo L, Mansueto S, Pignataro G, Grago F (2015) Do the current performance-based schemes in Italy really work? “Success fee”: A novel measure for cost-containment of drug expenditure. Value Health 18(1):131–136.Crossref, Google Scholar
• NCI (2019) National Cancer Institute Dictionary of cancer terms: Kymriah. Accessed February 20, 2019, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/kymriah.Google Scholar
• Neumann PJ, Chambers JD, Simon F, Meckley LM (2011) Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Affairs 30(12):2329–2337.Crossref, Google Scholar
• O’Brien BJ, Gertsen K, Willan AR, Faulkner LA (2002) Is there a kink in consumers’ threshold value for cost-effectiveness in healthcare? Health Econom. 11(2):175–180.Crossref, Google Scholar
• Olsder W, Martagan T, Tang CS (2019) Improving access to rare disease treatments: Optimal subsidies, pricing, and payment. Working paper, Eindhoven University of Technology, Eindhoven, Netherlands.Google Scholar
• Pagliarulo N (2019) Praluent scores heart label, matching Amgen’s rival Repatha. Accessed July 15, 2019, https://www.biopharmadive.com/news/praluent-cardiovascular-approval-label-amgen-pcsk9/553611/.Google Scholar
• Papanicolas I, Woskie LR, Jha AK (2018) Healthcare spending in the United States and other high-income countries. JAMA 319(10):1024–1039.Crossref, Google Scholar
• Rasiel EB, Weinfurt KP, Schulman KA (2005) Can prospect theory explain risk-seeking behavior by terminally ill patients? Medical Decision Making 25(6):609–613.Crossref, Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, et al. (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. New England J. Medicine 376(18):1713–1722.Crossref, Google Scholar
• Seeley E, Kesselheim AS (2017) Outcomes-based pharmaceutical contracts: An answer to high U.S. drug spending? Technical report, The Commonwealth Fund, New York.Google Scholar
• Thomas K, Ornstein C (2017) Considering the side effects of drugmakers’ money-back guarantees. New York Times (July 10), https://www.nytimes.com/2017/07/10/health/prescription-drugs-cost.html.Google Scholar
• Torrey T (2018) What is a health insurer’s drug formulary and tier pricing? Accessed February 13, 2019, https://www.verywellhealth.com/drug-formulary-tiers-pricing-health-insurance-plans-2615042.Google Scholar
• Treadwell JR, Lenert LA (1999) Health values and prospect theory. Medical Decision Making 19(3):344–352.Crossref, Google Scholar
• Tversky A, Kahneman D (1986) Rational choice and the framing of decisions. J. Bus. 59(4):S251–S278.Crossref, Google Scholar
• Tversky A, Kahneman D (1992) Advances in prospect theory: Cumulative representation of uncertainty. J. Risk Uncertainty 5(4):297–323.Crossref, Google Scholar
• Xu L, Li H, Zhao H (2019) Outcome-based reimbursement: The solution to high drug spending? Working paper, The Pennsylvania State University, State College.Google Scholar
• Yapar O, Chick SE, Gans N (2019) Risk-sharing agreements for new medical treatments. Working paper, University of Pennsylvania, Philadelphia.Google Scholar